Papers
Topics
Authors
Recent
Search
2000 character limit reached

Comparative optic and dosimetric characterization of the HYPERSCINT scintillation dosimetry research platform for multipoint applications

Published 30 Oct 2020 in physics.ins-det and physics.med-ph | (2011.00026v3)

Abstract: This study introduces the HYPERSCINT research platform, the first commercially available scintillation dosimetry platform capable of multi-point dosimetry through the hyperspectral approach. Optic and dosimetric performances of the system were investigated through comparison with another commercially available solution, the Ocean Optics QE65Pro spectrometer. The optical characterization was accomplished by measuring the linearity of the signal as a function of integration time, photon detection efficiency and spectral resolution for both systems. Dosimetric performances were then evaluated with a 3-point plastic scintillator detector (mPSD) in terms of signal to noise ratio (SNR) and signal to background ratio (SBR) associated with each scintillator. The latter were subsequently compared with those found in the literature for the Exradin W1, a single-point plastic scintillator detector. Finally, various beam measurements were realized with the HYPERSCINT platform to evaluate its ability to perform clinical photon beam dosimetry. Both systems were found to be comparable in terms of linearity of the signal as a function of the intensity. Although the QE65Pro possesses a higher spectral resolution, the detection efficency of the HYPERSCINT is up to 1000 time greater. Dosimetric measurements shows that the latter also offers a better SNR and SBR, surpassing even the SNR of the Exradin W1 single-point PSD. While the doses ranging from 1 cGy to 600 cGy were accurately measured within 2.1% of the predicted dose using the HYPERSCINT platform coupled to the mPSD, the Ocean optics spectrometer shows discrepencies up to 86% under 50cGy. Similarly, depth dose, full width at half maximum region of the beam profile and output factors were all accurately measured within 2.3% of the predicted dose using the HYPERSCINT platform and exhibit an average difference of 0.5%, 1.6% and 0.6%, respectively.

Summary

Paper to Video (Beta)

Whiteboard

No one has generated a whiteboard explanation for this paper yet.

Open Problems

We haven't generated a list of open problems mentioned in this paper yet.

Continue Learning

We haven't generated follow-up questions for this paper yet.

Collections

Sign up for free to add this paper to one or more collections.